Abstract Details
|
Ken Myers, MD, PhD
(Montreal Children'S Hospital/McGill University Health Centre)
PRESENTER |
Dr. Myers has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Myers has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharmaceuticals. Dr. Myers has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pendopharm. Dr. Myers has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AS2Bio. The institution of Dr. Myers has received research support from Fonds de Recherche de Santé Québec. The institution of Dr. Myers has received research support from Liam Foundation. The institution of Dr. Myers has received research support from Pediatric Research Foundation. The institution of Dr. Myers has received research support from Montreal Children's Hospital Foundation. The institution of Dr. Myers has received research support from CQDM/Pharma Liam. The institution of Dr. Myers has received research support from CIHR. |
| Luis E. Bello-Espinosa, MD, FÂ鶹´«Ã½Ó³» (Arnold Palmer Hospital for Children) | Dr. Bello-Espinosa has nothing to disclose. |
| Morris H. Scantlebury, MD (Alberta Childrens Hospital and Alberta Childrens Hospital Research Institute) | No disclosure on file |
| No disclosure on file |